|
|
| Year : 2002 | Volume
: 23
| Issue : 1 | Page : 4-7 |
|
|
Comparison of 5-fluorouracil and leucovorin versus 5-fluorouracil, leucovorin and oxaliplatin in measurable metastatic colorectal malignancy.
Yas V V, KM Patel, PM Shah, SN Shukla, BJ Parikh, AS Anand, SS Talati, SA Shah, B Parekh, S Nath, HP Panchal, AA Patel, B Shah, S Thuruthal, P Mehta
Department of Medical Oncology, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India
Correspondence Address:
Yas V V
Department of Medical Oncology, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
Colorectal carcinoma (CRC) accounts for 2.3 per cent of all cancers in our Institute as against 9.4 per cent at the international level. Of all deaths due to cancer at GCRI, 2.4 per cent deaths are attributed to CRC as against 7.9 per cent in the global the statistics. Due to lack of other active agents, 5-fluorouracil and leucovorin remained the treatment option over many years. Recently, positive results have been reported with addition of oxaliplatin to 5-fluorouracil and leucovorin. From March 1999 to September-2000, 32 patients were enrolled, 15 in the arm A containing 5-fluorouracil and leucovorin and 17 in the arm B containing 5-fluorouracil, leucovorin and oxaliplatin in measurable metastatic colorectal malignancy. No complete response was observed in either of the arms. Partial response was seen in 27 per cent in the arm A and 33.3 per cent in the arm B. The median duration of progression free survival in partial responders in the arm B it was 10 months, the difference, however, is not statistically significant as observed by log rank test (p=0.02342). To conclude, the addition of oxaliplatin to standard 5-fluorouracil and leucovorin increases the response rate, median progression free survival and overall survival, but none of these changes reached the statistical significance. |
|
|
|
| [PDF Not available]* |
|
 |
|
